date,title,source
Oct-23-18,Imprimis Pharmaceuticals Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt Conscious Sedation Drug Candidate,GlobeNewswire
